About 166,898 results

Lower bevacizumab doses, agents with less systemic exposure may be safer options for ROP

Feb 3rd, 2022 - WAIKOLOA, Hawaii — Systemic effects of anti-VEGF in retinopathy of prematurity have not been ruled out, so it may be wise to use bevacizumab in lower doses or switch to agents with less systemic exposure, according to one presenter. “The BEAT-ROP study demonstrated a beneficial effect for bevacizumab vs. laser in the treatment of zone I, stage 3+ ROP. But one thing I didn’t like was the complet...

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

Sep 9th, 2022 - The hypothesis is that the addition of daratumumab administered SC to standard MM regimens will improve responses compared to response data observed in completed phase 3 studies without daratumumab. Disease evaluations will include measurements of myeloma proteins, bone marrow examinations, skeletal surveys, assessment of extramedullary plasmacytomas, and measurements of serum calcium corrected...

Characteristics of Patients with Primary Retinal Vasculitis at a Tertiary Referral Center
Akash Gupta, Paola Rivera Morales2 and Ninani Kombo, Departmnt of Medicine et. al.

Nov 14th, 2022 - Background/Purpose: Primary retinal vasculitis (PRV) refers to inflammation in the retinal vasculature without any infectious etiology, systemic disease association, or concomitant ocular disease. PRV is a diagnosis of exclusion. Retinal vasculitis patients usually undergo a thorough diagnostic evaluation to search for an underlying systemic association and often require visits from multiple sp...

Clinical Outcomes Following Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Vaccination in Patients with Anti-Melanoma Differentiation Associated Gene 5 (MDA5) Antibody P...
Richard Seto, Sangmee Bae1 and Christina Charles-Schoeman, University of California Los Angeles et. al.

Nov 14th, 2022 - Background/Purpose: Patients with dermatomyositis (DM) and antibodies (ab) to melanoma differentiation associated gene 5 (MDA5) share similar clinical characteristics to patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) including high risk of fatal, rapidly progressive interstitial lung disease (RP-ILD). Nearly 50% of patients with COVID 19 have anti-MDA5 a...

Clinical Outcomes in an Observational Retrospective Cohort of Patients with Connective Tissue Disease-associated Interstitial Lung Disease (CTD-ILD) Who Taper Immunosuppressive Therapy
Paul Dellaripa, Paul Hoover and Tracy Doyle, Brigham and Women's Hospital et. al.

Nov 14th, 2022 - Background/Purpose: Patients with CTD-ILD are often treated with a combination of corticosteroids and steroid sparing agents to limit the progression of the inflammatory response in the lung and prevent remodeling that can lead to fibrosis. While tapering regimens for steroids are part of the standard of care in CTD-ILD, there is no significant experience on outcomes in patients who taper stero...

Canakinumab Treatment in Familial Mediterranean Fever Patients with Colchicine Resistance: A Single-center Study
Ibrahim Durucan, Ali Yagiz Ayla, Helin Idil Besiroglu et. al.

Nov 14th, 2022 - Background/Purpose: Recurrent fever and serositis are the hallmarks of Familial Mediterranean fever (FMF). Colchicine is known for yielding high success in disease control by obviating attacks; however, management of the disease may be challenging in the case of colchicine resistance. In this specific group, which consists 5-10% of FMF patients, induction of biological agents targeting inflamma...

Epidemiology of Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES) in Germany: A Claims Database Study
Bernhard Hellmich, Konstantin Neukirch, Marco Lukas et. al.

Nov 14th, 2022 - Background/Purpose: EGPA and HES are rare multisystemic diseases associated with eosinophilia. Robust data on the epidemiology and treatment of HES and EGPA are scarce. The aim of this study was to describe the epidemiology and treatment of HES and EGPA in Germany by analyzing population-based health claims data. Methods: The study was conducted with the InGef research database, which contains ...

Clinical Features and Long-term Outcomes of Patients with Systemic Polyarteritis Nodosa Diagnosed Since 2005: Data from 196 Patients
Julien ROHMER, ludovic trefond, Yann Nguyen et. al.

Nov 14th, 2022 - Background/Purpose: The etiological landscape of systemic polyarteritis nodosa (PAN) has substantially changed since the onset of hepatitis B virus (HBV) vaccination and the discovery of new entities such as adenosine deaminase 2 (ADA2) deficiency or PAN related to myelodysplastic syndrome (MDS) or hematological malignancies. Recent data regarding the current picture of systemic PAN, especially...

Invasive Fungal Diseases in Patients with Autoimmune Diseases: Prospective Data from a Nationwide French Registry
Simon Galmiche, Benjamin Thoreau, Stéphane Bretagne et. al.

Nov 14th, 2022 - Background/Purpose: Patients with autoimmune diseases (AIDs) display a risk of invasive fungal diseases (IFDs), because of the underlying disease or treatments used. Our objective was to describe the characteristics of IFDs in patients with AID and factors associated with mortality. Methods: We analysed IFD cases included into a prospective multicenter registry conducted by the French national ...

Sustained B Cell Depletion in Lupus Nephritis Patients After Treatment with a B Cell Agent Is Associated with Fewer Disease Flares
Diane Zisa, Jeffrey Zhang-Sun, Paul Christos2 and Kyriakos Kirou et. al.

Nov 14th, 2022 - Background/Purpose: B cell targeting agents (BCA), including belimumab (BEL) and rituximab (RTX), have been used with success in lupus nephritis (LN) patients, though identifying patients at highest risk for flare after receipt of these agents has not been well studied. We hypothesized that sustained low peripheral B cell counts (BCC) after successful control of LN would be associated with fewe...

Key Differences Between US Rheumatologists’ and Dermatologists’ Management of Psoriatic Arthritis
Maxine Yarnall, Spherix Global Insights, Exton et. al.

Nov 14th, 2022 - Background/Purpose: The last few years have seen the approval of many new agents for the treatment of psoriatic arthritis (PsA) and psoriasis (PSO), resulting in greater options for managing moderate to severe disease. Many of these newer agents (guselkumab, upadacitinib, risankizumab) have been approved for both PSO and PsA. As such, dermatologists’ biologic armamentarium closely parallels tha...

Pediatric Idiopathic Pulmonary Hemosiderosis – a Single-Center, Retrospective Study Comparing Use of Commonly Used Steroid-Sparing Agents
Melissa Argraves, Melissa Lerman, Julie Chase2 and Samuel Goldfarb et. al.

Nov 14th, 2022 - Background/Purpose: Idiopathic Pulmonary Hemosiderosis (IPH) is a rare, pediatric predominant condition causing episodic diffuse alveolar hemorrhage, which can be recurrent and life-threatening. Chronic steroid use has decreased overall mortality. Steroid sparing agents (SSA) are often used in recurrent disease in an attempt to limit corticosteroid (CS) toxicity. There are limited data describi...

Reading the Waves: Identifying Distinct Phenotypes of Multisystem Inflammatory Syndrome in Children During the 2020-2021 COVID-19 Pandemic
Thomas Renson, Nils Forkert, Kimberly Amador et. al.

Nov 14th, 2022 - Background/Purpose: The COVID-19-associated multisystem inflammatory syndrome in children (MIS-C) is characterized by Kawasaki disease (KD)-like mucocutaneous features. The clinical course is often unpredictable. The goals of the current study were (a) to compare MIS-C phenotypes across the different waves of the COVID-19 pandemic, and (b) to identify variables associated with pediatric intensi...

Effectiveness and Safety of Adalimumab versus Leflunomide in Patients with Takayasu Arteritis – a Retrospective Cohort Study
Faustino Peron Filho, Andressa de Souza Moreira, Anna Larissa Janes2 and Alexandre Wagner de Souza et. al.

Nov 13th, 2022 - Background/Purpose: Therapy for Takayasu arteritis (TAK) is based on the combination of high-dose glucocorticoids and immunosuppressive and/or biologic agents. Patients presenting severe disease manifestations are usually treated with TNF inhibitors (TNFi) even as first-line therapy. However, no comparative studies have been performed to compare the effectiveness of biologic agents versus immun...

Treatment of Polymyalgia Rheumatica by Rheumatology Providers: Results from the ACR Rheumatology Informatics System for Effectiveness Registry
Sebastian Sattui, Zihan Wan, Fenglong Xie et. al.

Nov 13th, 2022 - Background/Purpose: Polymyalgia rheumatica (PMR) is one of the most common systemic rheumatic diseases in older adults. Glucocorticoids (GC) remain the main treatment, and although recommendations suggest discontinuing GC after 1-2 years, prolonged use occurs in a significant proportion of patients. Patients with PMR treated by rheumatology providers are presumably more refractory, and with eme...

Low Circulating B Cells Correlate with Unresponsiveness to COVID-19 Vaccination Among Patients Treated with Rituximab
Christopher Halbur, Erin Sternhagen, Mohamad Dave Dimachkie2 and Petar Lenert et. al.

Nov 13th, 2022 - Background/Purpose: Rituximab impairs humoral immunity by depleting CD20+ B cells. Previous studies have demonstrated that patients on rituximab have decreased immune response to COVID-19 vaccination. However, prior studies have not fully delineated the effect of patient characteristics, treatment protocol, timing of vaccination, and B cell levels on antibody response. This study aims to assess...

Lung Involvement in VEXAS Syndrome
Marta Casal Moura, Misbah Baqir, Yasmeen Tandon et. al.

Nov 13th, 2022 - Background/Purpose: Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is a recently identified disorder caused by somatic mutations in the UBA1 gene of myeloid cells. Pulmonary involvement has been reported, but a detailed description of lung involvement and radiologic findings is lacking. Methods: A retrospective cohort study was conducted of all patients identified at ...

Breakthrough SARS-CoV-2 Infections in Immune Mediated Disease Patients Undergoing B Cell Depleting Therapy: A Retrospective Cohort Analysis
Cassandra Calabrese, Elizabeth Kirchner, M. Elaine Husni et. al.

Nov 13th, 2022 - Background/Purpose: Immunocompromised patients with immune mediated inflammatory diseases (IMIDs) undergoing therapy with B cell depleting agents (BCDT) are among the most vulnerable to severe COVID-19 infection as well as the most likely to respond sub-optimally to SARS-CoV-2 vaccines. However, little is known about the frequency or severity of breakthrough infection in this population. We ret...

Post-mRNA Vaccine Flares in Autoimmune Inflammatory Rheumatic Diseases: Results from the COronavirus National Vaccine Registry for ImmuNe Diseases SINGapore (CONVIN-SING)
Margaret Ma, Amelia Santosa, Kok Ooi Kong et. al.

Nov 13th, 2022 - Background/Purpose: Published data suggest no increased rate of flare of autoimmune inflammatory rheumatic diseases (AIIRD) after COVID-19 mRNA vaccination; however, the studies are limited by small sample size, short follow up or at risk of selection bias (voluntary physician reports or patient surveys). Therefore, our aim is to study flares of AIIRD within three months of the first dose of an...

Low-dose Belimumab and Antimalarial Agents Prevent Renal Flares in Systemic Lupus Erythematosus: Results from Four Randomised Clinical Trials
Alvaro Gomez, Sandra Jägerback, Christopher Sjöwall2 and Ioannis Parodis et. al.

Nov 13th, 2022 - Background/Purpose: Renal flares contribute substantially to morbidity, renal survival and death in systemic lupus erythematosus (SLE). Identification of pharmacological strategies for the prevention of renal flares is a key unmet need in SLE treatment. In the present study, we tested the hypothesis that the use of belimumab and antimalarial agents (AMA) protects against the development of rena...